Metraipolis › archive › dc_8a473a1b77fc

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative… — Europe PMC PMID:41022779

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41022779
DOI
10.1038/s41523-[numero omesso]-6
License (as archived)
solo-consultazione
Archived
2026-11-09T17:37:10.267Z
SHA-256 of the archived text
1e5d7363ef082a882a061be2cfedae73e8c602dee5e4a19e915f68c681b29e3f
Stable URL of this page
https://metraipolis.com/documento/dc_8a473a1b77fc

How to cite

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative… — Europe PMC PMID:41022779 — Europe PMC (en), https://europepmc.org/article/MED/41022779 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a473a1b77fc (Metraipolis archive dc_8a473a1b77fc, sha256 1e5d7363ef082a882a061be2cfedae73e8c602dee5e4a19e915f68c681b29e3f)
BibTeX
@misc{dc8a473a1b77fc,
  title = {Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative… — Europe PMC PMID:41022779},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41022779},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a473a1b77fc; sha256 1e5d7363ef082a882a061be2cfedae73e8c602dee5e4a19e915f68c681b29e3f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41022779. Agents can read the archived copy with the MCP tool read_document.